Task: Translation
Input (Czech): e en  se t²k  slou enin obecn ho vzorce I, kde R.sup.1.n. p°edstavuje atom vod ku, hydroxylovou skupinu, skupinu -O(C.sub.1.n.-C.sub.4.n. alkyl), -OCOC.sub.6.n.H.sub.5.n., -OCO(C.sub.1.n.-C.sub.6.n. alkyl) nebo -OSO.sub.2.n.(C.sub.4.n.-C.sub.6.n. alkyl); R.sup.2.n. p°edstavuje C.sub.1.n.-C.sub.6.n. alkylovou skupinu, C.sub.5.n.-C.sub.7.n. cykloalkyl, kter² je pop° pad  substituovan² 1 a  3 substituenty vybran²mi ze souboru zahrnuj c ho C.sub.1.n.-C.sub.4.n. alkylovou skupinu, C.sub.1.n.-C.sub.4.n. alkoxylovou skupinu, hydroxyskupinu, aminoskupinu, nitroskupinu, a atom halogenu; X p°edstavuje skupinu -CH(OH)- nebo -CH.sub.2.n.-; M p°edstavuje skupinu -CH.sub.2.n.CH.sub.2.n.- nebo -CH=CH-; n p°edstavuje   slo 2 nebo 3; a R.sup.3.n. p°edstavuje skupiny 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrroli-dinyl, 4-morfolino, dimethylamino, diethylamino nebo 1-hexamethylenimino; nebo jej  farmaceuticky p°ijateln  s l nebo solv t.  e en  se tak  t²k  zp sobu pou it  slou enin podle p°edkl dan ho vyn lezu pro l  en  r zn²ch l ka°sk²ch indikac , souvisej c ch s postmenopaus ln m syndromem, d lo n m fibroidn m onemocn n m, endometri zou a proliferac  bun k aort ln ho hladk ho svalstva.  e en  se tak  t²k  farmaceutick²ch kompozic, obsahuj c ch slou eniny obecn ho vzorce I a meziprodukt  p°i p° prav  slou enin obecn ho vzorce I.\
Output (English): In the present invention there are disclosed compounds of the general formula I, in which Re1 represents a hydrogen atom, a hydroxyl group, the group -O(Ci1-Ci4 alkyl), -OCOCi6Hi5, -OCO(Ci1-Ci6 alkyl) or -OSOi2(Ci4-Ci6 alkyl); Re2 represents alkyl group containing 1 to 6 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, and can be optionally substituted with 1 to 3 substituents being selected from the group comprising alkyl group containing 1 to 4 carbon atoms, alkoxyl group having 1 to 4 carbon atoms, a hydroxy group, an amino group, a nitro group, and a halogen atom; X represents the group -CH(OH)- or -CHi2-; M represents the group -CHi2CHi2- or -CH=CH-; n is the number 2 or 3; and Re3 represents the 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrroli-dinyl, 4-morpholino, dimethylamino, diethylamino or 1-hexamethylenimino group or pharmaceutically acceptable salt or solvate thereof. The invention also relates to a method of using the compounds according to the present invention for treating various medicinal indications connected with postmenopausal syndrome, uterine fibroid disease, endometriosis and cell proliferation of  aortal smooth musculature. In the present invention there are also claimed disclosed pharmaceutical compositions containing compounds of the general formula I and intermediates for preparing the compounds of the general formula I.